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Abstract 
 
We examined machine learning methods to predict death within six months using data derived 
from the United States Renal Data System (USRDS). We specifically evaluated a generalized 
linear model, a support vector machine, a decision tree and a random forest evaluated within the 
context of K-10 fold validation using the CARET package available within the open source 
architecture R program. We compared these models with the feed forward neural network 
strategy that we previously reported on with this data set.  
 
Keywords 
 
hypertension, blood pressure, chronic renal disease, correlation, machine learning  
 
Introduction 
 
Patients with end stage renal disease (ESRD) have an extremely high extra renal morbidity and 
age adjusted mortality compared with the general population in the United States.1-3 A number of 
factors have been identified which predict risk in this patient population, and some of these factors 
are reasonably powerful at predicting risk.4-8 We have previously reported on patient records kept 
within the United States Renal Data System (USRDS);9 a number of qualitative and quantitative 
measurements are presented which can be accessed rather easily from the National Institutes of 
Health.10,11 In our previous study, we found that a neural network approach was not superior to 
that obtainable with a logistic linear approach at predicting time to death. However, since that 
report, advances in machine learning have allowed for the relatively easy application of other 
approaches which might help clinicians estimate mortality risk in this population. For that reason, 
the following study was performed.  
Methods 
 
Files containing de-identified patient records from the USRDS in 2007 were read in the program 
SAS (version 9.1), SAS Institute Inc., Cary, NC, and exported in a CSV format. Forty-two 
variables were selected to be used in the analysis based on their potential clinical significance 
and their wide availability within the USRDS as we had previously reported.9  
 
All analysis was performed using the open source program R. We used a generalized linear 
model as our default.12 In addition, we examined the utility of a support vector machine,13 
decision trees with the RPART package, neural networks (1 hidden layer, feed forward as 
previously studied(9)),  and random forests.14,15  The CARET package was used for comparison 
of the mature models employing 10 K- folds and 3 repeats performed on a training set (5% of 
total) chosen with different randomization seeds to allow for reproducibility.16 Other packages 
within R were used for different specific tasks (e.g., NNet for construction of the neural network, 
randomForest (RFor) for constructing random forests)17 as we recently demonstrated with the 
Modification of Diet with Renal Disease (MDRD) dataset.18  
 
For these studies, we focused on the categorical output of survival less than six months. This 
outcome variable was chosen for its clinical relevance to nephrology practice.  
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Results and Discussion 
 
In the records that were selected for analysis, just over 67 thousand subjects died within the first 
six months of starting hemodialysis (HD) therapy whereas the remaining 330 thousand subjects 
survived longer. The data in these two groups are summarized in Table 1. Those that died early 
tended to have poorer nutrition as evidenced by a lower serum albumin, serum creatinine (SCr) 
and body mass index (BMI) (all p<0.01). They also tended to be significantly older (68.3+/15.0 
vs 61.3+/-15.8, p<0.01), have a lower prevalence of insulin dependent diabetes (p<0.01) and 
higher EPO dosages (p<0.01). The prevalence of ischemic heart disease and prevalence of 
pulmonary disease were both higher in those dying early (both p<0.01). Many of the data were 
quite similar in the two groups although because of the large numbers involved, statistical 
significance was noted (Table 1).  The high rates of HIV and AIDS reflects the time that these 
data were obtained; it is quite likely that a more recent data set would have much lower 
prevalence for HIV and related conditions.  
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Table 1: Comparison of Early Death (< 6 months) and Others 
 Not Dead at 6 months Dead at 6 months P value 
N 330452 67139  
Hemoglobin 9.79+/-1.67 9.96+/-1.62 P<0.01 
Albumin 3.16+/-0.67 2.95+/-0.68 P<0.01 
SCr 7.45+/-3.41 6.41+/-3.00 P<0.01 
BMI 27.3+/-7.0 26.0+/-6.7 P<0.01 
BUN 82.9+/-27.6 83.8+/-29.2 P<0.01 
SEX 53%Male 53%Male NS 
RACE 59%White 31% Black 
10% other 
71%White 22% Black  
7% other 
P<0.01 
AGE 61.3+/-15.8 68.3+/-15.0 P<0.01 
DIALYSIS 
SETTING 
91% In Center 93% In Center P<0.01 
DIALYSIS 
TYPE 
93% IHD 96% IHD P<0.01 
INCIDENT 
ESRD AGE 
62.6+/-15.6 69.3+/-14.5 P<0.01 
AIDS 19%  17%  P<0.01 
HIV 19%  17%  P<0.01 
ALCOH 1.3%  2.0%  P<0.01  
CANCER 5.1%  10,2%  P<0.01 
CARFAIL 31%  42%  P<0.01 
CVA 9%  13%  P<0.01 
INSULIN 24%  21%  P<0.01 
DIABETES 
PRIMARY DX 
46%  41%  P<0.01 
DRUG 1.1%  1.0%  P<0.05 
DYYSRYTH 5.6% 10.4% P<0.01 
EPO 68% 75% P<0.01 
HYPER 81% 72% P<0.01 
Ischemic Heart 
Disease 
24% 32% P<0.01 
MI 8% 12% P<0.01 
NOAMBGUL 3.3% 9.1% P<0.01 
PERICARD 0.7% 0.7% NS 
PULMON 6.9% 11.7% P<0.01 
PVASC 14% 19% P<0.01 
SMOKE 5.6% 4.8% P<0.01 
*Note that because number of subjects is so high in both groups, confidence intervals around 
point estimate for prevalence are <<1% for all categorical values.  
SCr – serum creatinine, BUN – serum urea nitrogen, ALCOH – alcohol dependency, CANCER 
– cancer present, CARFAIL- cardiac failure, CVA – cerebrovascular accident, HIV – human 
immunodeficiency virus positive, AIDS – acquired immunodeficiency syndrome present,  
DRUG – drug dependency, DYYSRYTH- cardiac arrhythmias, EPO – erythropoietin utilization, 
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HYPER – hypertension present, Ischemic Heart Disease present, MI – history of myocardial 
infarction, NOAMBGUL- not able to ambulate, PERICARD – pericarditis, PULMON – 
pulmonary disease present, PVASC – peripheral vascular disease present, SMOKE – active 
smoker.  
 
Different machine learning approaches yielded somewhat different fits as assessed by ROC 
curves (Figure 1, Table 2). In general, the best fits were obtained by either the generalized linear 
model (logistic regression, GLM) or the random forest (RForest) approach with the feed-forward 
neural network (NNet) just slightly behind. The SVM was next with the decision tree (RPart) 
least effective. Because the decision tree method was so weak, we did not investigate its 
predictions further. In contrast to the ROC curves which demonstrated significant differences 
(Table 2), the accuracy values obtained by the remaining four methods were remarkably similar 
although statistical inferiority to the linear model was evidenced by both the SVM and the NNet 
models. Accuracy achieved by the Rforest was similar to that obtained by the GLM. Sensitivity 
of the GLM was inferior to that obtained by the SVM and RForest methods whereas specificity 
of the NNet method was the best. Along those lines the NNet method had the highest positive 
predictive value (PPV) where the RForest had the highest negative predictive value (NPV).  
These data are all summarized in Table 3.  
 
 
Figure 1: Receiver operator curves (ROC) achieved with generalized linear model (GLM) 
- red, support vector machine (SVM) – green, decision tree (RPart) – blue, feed forward 
neural network (NNet) – orange and random forest (RFor) – purple on testing set (95%) 
after training on training set (5%) with seed 33 used for randomization.   
 
 
 
 
79
Khitan et al.: Machine Learning and the USRDS
Published by Marshall University's Joan C. Edwards School of Medicine, 2018
  
Table 2: ROC areas with the different methods: 
 GLM SVM RPart NNet RForest 
Mean 0.7140 0.6546 0.6119 0.6980 0.7152 
SD 0.0007 0.0114 0.0087 0.0023 0.0006 
P value  P<0.01 P<0.01 P<0.01  
GLM – generalized linear model, SVM – support vector machine, RPart – decision tree, NNet – 
feed forward neural network with 1 hidden layer, RForest – random forest. P value vs GLM. 
Each ROC determined for each method with 6 different seed values to generate selection of 
training and testing sets. Training sets chosen to 5% of the total patient records.  
 
Table 3: Diagnostic accuracy with different methods: Calculated from N=6 seeds.  
 GLM SVM RPart NNet RForest 
Accuracy 0.8319+/-
0.0002 
0.8311+/-
0.0001** ND 
0.8272+/-
0.0004** 
0.8317+/-
0.0001 
Kappa 0.073+/-
0.005 
0.013+/-
0.008** ND 
0.091+/-
0.006** 
0.048+/-
0.004** 
Sensitivity 0.989+/-
0.001 
0.998+/-
0.001** 
ND 0.978+/-
0.002** 
0.993+/-
0.001** 
Specificity 0.058+/-
0.005 
0.010+/-
0.006** 
ND 0.084+/-
0.006** 
0.037+/-
0.004** 
PPV 0.838+/-
0.001 
0.832+/-
0.001** 
ND 0.840+/-
0.001** 
0.835+/-
0.001** 
NPV 0.521+/-
0.009 
0.491+/-
0.032** 
ND 0.440+/-
0.005** 
0.526+/-
0.007 
Data shown as mean +/- SD of six determinations. PPV – positive predictive value, NPV – 
negative predictive value. Positive class is “alive > 6 months.” ** p<0.01 vs GLM.  
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The factors that were most important to the models are shown in Table 4. It is clear that patient 
age, serum creatinine and serum albumin are important to the different models. Other 
measurements made it to the top of some of the models but not others. The different models were 
remarkably consistent with the importance order with which variables were chosen with the 
different seeds (data not shown).  
  
Table 4: Variable importance among the different methods  
 GLM SVM NNet RForest 
1 
Albumin Age 
Disease 
Group Age 
2 
Disease Group 81% 
Incident Age 
98% 
Age 77% 
 
BMI 
 92% 
3 Non-Ambulatory 78% SCr 69% SCr 72% SCr 86% 
4 Hypertension 
70% 
Albumin 57% Albumin  
67% 
BUN  
81% 
5 EPO  
58% 
DisGrp 45% Incident Age 63% Albumin 74% 
Albumin- serum albumin, Incident Age – age of first ESRD treatment, SCr – serum creatinine, 
BUN – serum urea nitrogen, EPO – erythropoietin use, Hypertension – presence of hypertension.  
 
 
As the entire data set had a relative paucity of early deaths, we examined how our algorithms 
performed with a balanced training set constructed from drawing from a subpopulation where the 
fraction of patients with early (< 6 month) deaths was 50:50. When we did this, all training 
algorithms had dramatic increases in kappa values (to about 0.2) as well as specificity values (to 
between 0.60 and 0.65) with marked decreases in sensitivity to be essentially matched to the 
specificity value obtained with that algorithm. As accuracy also decreased by about 20%, we 
chose to leave the training dataset unbalanced. Manuscripts addressing the challenge of 
unbalanced data sets recognize this problem but do not offer a universal solution.19  
 
The results we observed were not very surprising based on our previous experience with this data 
set where we saw that the neural network model did not afford advantages over linear or 
actuarial strategies at predicting time to death.9 In the current study, the logistic linear model (as 
we were predicting a categorical outcome) was, to all intents and purposes, comparable or 
superior to more sophisticated strategies at predicting early death after the initiation of dialysis 
therapy. Cross talk between variables clearly wasn’t all that important in the determination of 
this important outcome; evidence strongly supported the contention that a logistic linear model 
captured most of the information present in this large data set.  
 
In the analysis performed, sensitivity was calculated based on the model’s ability to predict 
survival.  Along with the high prevalence of survivors, the positive predictive value was 
generally in excess of 80%. This seems to be more than high enough to merit a trial of dialytic 
therapy. In contrast, the negative predictive value of the models hovered around 50%. Frankly, 
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this does not come close to meeting the authors’ threshold for futility of care, and it would seem 
irresponsible to withhold dialytic therapy for such a prediction. However, it seems that such a 
prediction might be of a precision sufficient to recommend additional vigilance in monitoring. 
With the ease of implementing the logistic linear model, this seems to be a reasonable approach 
based on the data used in this study which are readily available from routine clinical records (and 
usually submitted with the CMS-2728-U3 form).  
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Appendix: 
rm(list=ls()) #empty memory 
setwd("C:/Users/shapiroj/Dropbox/Current Stuff/work") #set working directory 
#load csv file and erase empty columns  
library(dplyr) 
dat <- read.csv("esrd.csv",stringsAsFactors=FALSE,na.string=c("",NA," ","U","Unk")) 
dim(dat) 
dat1 = dat[,!apply(is.na(dat), 2, all)]   # automatically get rid of empty cols at the end 
#set up outcome variable as “yes”  or “no” for subsequent machine learning 
A=NULL 
mm=dim(dat1)[1] 
for(i in 1:mm){ 
if(dat1[i,39]<6){ 
A[i]="yes" 
}else{ 
A[i]="no" 
} 
} 
#make all data used for fitting numeric; essential for most machine learning algorithms 
dat2=dat1[,1:38] 
for(i in 1:38){ 
  dat2[,i]=as.numeric(dat2[,i]) 
} 
#reconstitute file z with output1 variable having outcomes as yes or no.  
z=cbind(dat2,A) 
colnames(z)[39]="output1" 
#clean up some variables 
z=z[,-c(1,5,38)] 
#load additional libraries 
library(rJava) 
library(ROCR) 
library(pROC) 
library(rpart) 
library(caret) 
library(nnet) 
library(C50) 
library(ggplot2) 
library(lattice) 
library(randomForest) 
library(rminer) 
library(xgboost) 
library(rBayesianOptimization)  ## Bayesian Optimization  
#run simulations and save data 
vv=c(2,33,15,19,5) #create vector with different seeds 
#loop with different seeds 
for(i in 1:5){ 
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  set.seed(k) 
  #split into training and testing subsets based on seed 
  ind = sample(2, nrow(z), replace = TRUE, prob = c(0.5, 0.95)) 
  trainset = z[ind == 1,] 
  testset = z[ind == 2,] 
  #save files with output data 
  vvv=paste0("esrd_10_seed_",k,".txt") 
  www=paste0("esrd_10_seed_",k,".png")   
  #set up training with CARET for different machine learning methods 
  control = trainControl(method = "repeatedcv", number = 10, repeats = 3, classProbs =  
  TRUE, summaryFunction = twoClassSummary) 
  glm.model = train(output1 ~ ., data = trainset, method = "glm", metric = "ROC", trControl =           
control, preProc=c("center","scale")) 
  tunGrid_svm=expand.grid(sigma=c(0.015), C=c(1)) #sigma and C fit optimized 
  separately based on ROC on training set 
  svm.model = train(output1 ~ ., data = trainset, method = "svmRadial",metric = "ROC", 
  tuneGrid=tunGrid_svm, trControl = control, preProc=c("center","scale")) 
  rpart.model = train(output1 ~ ., data = trainset, method = "rpart", metric = "ROC", 
  trControl = control, preProc=c("center","scale")) 
  tunGrid=expand.grid(size=c(9),decay=c(0.2)) #number of hidden neurons (size) and  
  decay rate optimized separately based on ROC on training set 
  nnet.model = train(output1 ~ ., data=trainset, method = "nnet", metric="ROC", 
  trace=FALSE, trControl=control, tuneGrid=tunGrid, 
  preProc=c("center","scale")) 
  tunegrid=expand.grid(.mtry=c(12)) #mtry which is number of branches to random forest  
  optimized based on ROC on training set 
  rfor.model = train(output1 ~ ., data=trainset, method = "rf", metric="ROC", 
  trControl=control,tuneGrid=tunegrid, preProc=c("center","scale")) 
  #make predictions based on models 
  glm.probs = predict(glm.model, testset[,! names(testset) %in% c("output1")], type = "prob") 
  svm.probs = predict(svm.model, testset[,! names(testset) %in% c("output1")], type = "prob") 
  rpart.probs = predict(rpart.model, testset[,! names(testset) %in% c("output1")], type = "prob") 
  nnet.probs=predict(nnet.model,  testset[,! names(testset) %in% c("output1")], type = "prob") 
  rfor.probs=predict(rfor.model,  testset[,! names(testset) %in% c("output1")], type = "prob") 
  #make ROC graphs 
  png(www) 
  glm.ROC = roc(response = testset[, c("output1")], predictor = glm.probs $yes, levels = 
  levels(testset[, c("output1")])) 
  plot(glm.ROC,add=F, col =" red",main=k) 
  svm.ROC = roc(response = testset[, c("output1")], predictor = svm.probs $yes, levels = 
  levels(testset[, c("output1")])) 
  plot(svm.ROC, add = TRUE, col ="green") 
  rpart.ROC = roc(response = testset[, c("output1")], predictor = rpart.probs $yes, levels = 
  levels(testset[, c("output1")])) 
  plot(rpart.ROC, add = TRUE, col ="blue") 
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  nnet.ROC=roc(response = testset[, c("output1")], predictor = nnet.probs $yes, levels = 
  levels(testset[, c("output1")])) 
  plot(nnet.ROC, add = TRUE, col ="orange") 
  rfor.ROC=roc(response = testset[, c("output1")], predictor = rfor.probs $yes, levels = 
  levels(testset[, c("output1")])) 
  plot(rfor.ROC, add = TRUE, col ="purple") 
  dev.off() #close ROC graph 
  sink(vvv) #open text output 
  #confusion matrices and variable importance lists 
  glm.pred=predict(glm.model,testset[,!names(testset)%in% c("output1")]) 
  t=table(glm.pred,testset[,c("output1")]) 
  tt=confusionMatrix(glm.pred,testset[,c("output1")]) 
  print("glm.model") 
  print(tt) 
  print(glm.ROC) 
  print(varImp(glm.model)) 
  svm.pred=predict(svm.model,testset[,!names(testset)%in% c("output1")]) 
  t=table(svm.pred,testset[,c("output1")]) 
  tt=confusionMatrix(svm.pred,testset[,c("output1")]) 
  print("svm.model") 
  print(tt)#  
  print(svm.ROC) 
  print(varImp(svm.model)) 
  rpart.pred=predict(rpart.model,testset[,!names(testset)%in% c("output1")]) 
  t= table(rpart.pred,testset[,c("output1")]) 
  tt=confusionMatrix(rpart.pred,testset[,c("output1")]) 
  print(rpart.ROC) 
  print(varImp(rpart.model)) 
  nnet.pred=predict(nnet.model,testset[,!names(testset)%in% c("output1")]) 
  t= table(nnet.pred,testset[,c("output1")]) 
  tt=confusionMatrix(nnet.pred,testset[,c("output1")]) 
  print("nnet.model") 
  print(tt) 
  print(nnet.ROC) 
  print(varImp(nnet.model)) 
  rfor.pred=predict(rfor.model,testset[,!names(testset)%in% c("output1")]) 
  t=table(rfor.pred,testset[,c("output1")]) 
  tt=confusionMatrix(rfor.pred,testset[,c("output1")]) 
  print("rfor.model") 
  print(tt) 
  print(rfor.ROC) 
  print(varImp(rfor.model)) 
  sink() #close text file 
  }#end loop 
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